US/UK/Canada

Share

Quotes

The patent significantly strengthens the intellectual property for BupiZenge® in Europe
Pirkko Tamsen, CEO of OncoZenge
It protects the use of BupiZenge® in all relevant indications for treatment of pain in the oral cavity
Pirkko Tamsen, CEO of OncoZenge
The great interest from well-reputed investors is very positive and enables BupiZenge® to further progress its clinical program and OncoZenge to become a listed company in the near future. I look forward to leading the continued development focusing on our upcoming Phase 3 study in an indication area with significant need for better treatment alternatives. The goal is to offer patients much better pain relief and to create value for our shareholders
Pirkko Tamsen, CEO of OncoZenge
The separate listing on Nasdaq First North and subsequent Rights Issue provide an opportunity to develop the potential in BupiZenge® and also provide shareholders of Moberg Pharma an opportunity to invest and participate in the value creation in OncoZenge
Anna Ljung, CEO of Moberg Pharma
Pick a time period -
Tags ( Active)

OncoZenge enters into SEK 30.2 million investment agreement with new strategic investor Sichuan Yangtian Bio-Pharmaceutical, intended to be carried out through directed share issues

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announces that the Company has entered into an investment agreement (the “Investment Agreement”)whereby the Chinese investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the “Investor”) has undertaken to subscribe for a maximum of 4,669,647 new shares in the Company at a subscription price of SEK 6.47 per share, which represents a premium of approximately 40 percent compared to the volume-weighted average price (VWAP) for the Company’s shares on Nasdaq First North Growth Market during a period of 20 trading days ending on 24 January 2025, and

OncoZenge AB files PCT patent application for BupiZenge™

STOCKHOLM, SWEDEN - January 16, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces the filing of a patent application under the Patent Cooperation Treaty (PCT) process, a significant milestone in the intellectual property strategy for the company’s lead drug candidate, BupiZenge™. This filing follows the patent application submitted with priority with the Swedish Patent and Registration Office (PRV) in February of 2024, in line with international PCT requirements.The PCT process is a crucial step toward obtaining broad international patent protection, offering the

OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

STOCKHOLM, SWEDEN – January 13, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces that the Company has entered into a non-binding agreement with the intention to partner with pharmaceutical leader Molteni Farmaceutici (“Molteni”) regarding exclusive rights to commercialization of BupiZenge™ in Europe.The Company has signed a non-binding offer from Molteni for a commercial partnership to introduce BupiZenge™ in Europe with the goal to sign the definitive licensing agreement no later than April 30th, 2025. During a period of exclusivity, the parties will complete planning,

OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa

STOCKHOLM, SWEDEN – October 18, 2024 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces the intention to partner with the global pharmaceutical leader Pharmanovia regarding exclusive rights to commercialization of BupiZenge™ in Europe, the Middle East, and Northern Africa (the “EMENA region”).The Company has signed a non-binding offer from Pharmanovia for a commercial partnership to introduce BupiZenge™ in Europe, the Middle East and Northern Africa. The parties will now enter a period of exclusivity to complete detailed due diligence and joint detailed planning, with the goal

OncoZenge participates in MASCC cancer care conference June 27-29

Stockholm, Sweden – June 4 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces its participation in the 2024 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting taking place in Lille, France on June 27-29, 2024.The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. Consistent with MASCC’s purpose the conference focuses on the latest advancements and best practices in cancer supportive

OncoZenge Appoints Anna Asplind as Phase 3 Program Manager

Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager.As previously communicated the OncoZenge strategy and focus is planning for a pivotal phase 3-program towards European market authorization of BupiZenge™, together with a partner. The company is still evaluating the best partner options and plans but is pleased to confirm the appointment of Anna Asplind as Phase 3 Program Manager in support of OncoZenge’s

OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs

Stockholm, Sweden – April 25 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the release of a report outlining the opportunity to address critical Unmet Medical Needs in oncology care.Pain remains one of the leading reasons for cancer treatment interuptions and significantly impacts Quality of Life during chemotherapy and radiotherapy. BupiZenge™ is uniquely positioned to help millions of patients, alleviating their oral pain stemming from oral mucositis, a common and debilitating side

OncoZenge Appoints Åsa Nilsson as Clinical Research Manager

Stockholm, Sweden – April 9 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Åsa Nilsson as Clinical Research Manager (CRM).As previously communicated the OncoZenge strategy and focus is planning for a pivotal phase 3-program towards European market authorization of BupiZenge™, together with a partner. The company is still evaluating the best partner options and plans but is pleased to confirm the appointment of Åsa Nilsson as Clinical Research Manager in support of

OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board

Stockholm, Sweden – April 8 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces that Dr. Paolo Bossi joins its Advisory Board.The OncoZenge Advisory Board was established in December 2023 with the objective of supporting the company in its efforts to lead BupiZenge™ through clinical development, market introduction and commercialization, with Dr Stephen Sonis and Dr Pooja Nandwani Patel as founding members. The company is pleased to now welcome Dr Paolo Bossi, Medical Oncologist and

OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™

Stockholm, Sweden – April 4, 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid based treatment for oral pain, announces today that ongoing stability studies for the revised formulation of BupiZenge™ show positive results.Stability studies of BupiZenge™ are ongoing in line with previous communication from the company. The data now obtained shows 3 months of positive results within the desired limits of the specification for the development of the latest formulation. This data complements earlier data and analyzes and confirms the

OncoZenge Explores Strategic Options for BupiZenge™ in China

STOCKHOLM, SWEDEN – March 11, 2024 – OncoZenge AB (publ), a pharmaceutical company dedicated to the development of innovative solutions for oral pain relief, today announces that Eurosin Capital AB has been retained as advisors to explore strategic options for the introduction of BupiZenge™ in China.”The Chinese market represents a significant opportunity for BupiZenge. More than 4 million people are diagnosed with cancer in China every year. With the typically high prevalence of oral mucositis during cancer treatments there is a clear need for safe and effective, local, non-opioid pain

OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™

Stockholm, February 7, 2024 – OncoZenge AB (publ) today announces that the company has filed a new patent application with the Swedish Patent and Registration Office (PRV). The patent strengthens the protection of the second generation of BupiZenge™ and the innovations made in connection with the recent reformulation. The new patent will provide strengthened IP protection for strategic partners and licensees upon approval.In line with OncoZenge's strategy, the company has assessed the opportunities for complementary patents that further strengthen the protection for the second generation

OncoZenge submits application for PRIME status in the EU

Stockholm, Sweden, January 2[nd] 2024 – OncoZenge AB (publ), a leading biotechnology company developing BupiZenge™, an innovative, opioid-sparing treatment for oral pain, today confirms the submission of an application for PRIME (Priority Medicines) status with the European Medicines Agency (EMA).The PRIME initiative offers early, proactive, and enhanced support to accelerate the evaluation of promising medicines, to reach patients faster. To be eligible for PRIME, medicines must target an unmet medical need and show potential benefits for patients based on clinical data.  BupiZenge™ is

OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel

Stockholm, Sweden, December 13th 2023 – OncoZenge AB (publ) (Nasdaq First North Growth Market: ONCOZ), a leading biotechnology company developing BupiZenge™, an innovative therapy for treating oral pain, today announces the formation of an Advisory Board of renowned scientists and clinicians with expertise in oral medicine and cancer.The Advisory Board will provide strategic guidance and consultation to OncoZenge as it advances its research and development, with a focus on advancing BupiZenge™ through phase III studies and eventual market approval. The board's members bring a wealth of

Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States

Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer TreatmentSAN DIEGO, CA and STOCKHOLM, Sweden – November 28, 2023 - Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, and OncoZenge AB (“OncoZenge”) (STO:ONCOZ), a clinical-stage company developing a transformative treatment for oral pain, are pleased to announce today that they have signed a letter of intent (LOI) to explore a strategic collaboration to

OncoZenge provides strategy update

On November 21st OncoZenge AB (publ) announced significant progress in the development of BupiZenge™, a novel non-opioid oral pain reliever. With that backdrop OncoZenge provides the following strategy update with focus on market potential and strategic partnering for accelerating BupiZenge™ towards market approval.As communicated in the company’s financial report for the 3rd quarter 2023 on October 31st, significant progress is being made towards the goals set out in the revised strategy communicated on September 9th. Furthermore, as communicated on November 21st, comprehensive analyses

The new formulation of OncoZenge’s drug candidate BupiZenge™ is clean

OncoZenge can today confirm that comprehensive analyses show that the adjusted formulation of BupiZenge™ is clean. Stability studies will now continue as planned. The company asserts that a clean and stable product formulation has great commercial value for potential licensees and strategic partners, as a proven, working product is the basis for continued clinical study and an eventual market approval.As announced in the financial report for the third quarter, the company has for some time analyzed the cause of the previously announced impurity in the lozenge formulation of BupiZengeTM. The

OncoZenge initiates toxicity study and announces modification to the clinical plan

OncoZenge AB (OMX: ONCOZ) has today commenced dosing in a toxicity study for its product candidate BupiZenge[®]. The study design is based on an advisory meeting with the Swedish Medical Agency and aims to document the safety of repeated oral topical administration of bupivacaine.Bupivacaine, which is the active pharmaceutical ingredient in BupiZenge[®], is the most widely used anesthetic for epidural anesthesia during childbirth, as well as for post-operative pain treatment. The compound and its safety profile has been extensively studied since it was first discovered more than sixty years

Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea

On November 16, 2020, OncoZenge AB (publ), Moberg Pharma's subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market. Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021. The Board of OncoZenge has today, with the support of an authorization from an Extraordinary General Meeting on January 21, 2021, decided on the terms for the rights issue of approximately SEK 60 million (the “Rights

OncoZenge announces issue of European Patent related to BupiZenge[®]

OncoZenge AB (publ), Moberg Pharma’s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge[®], currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032.The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients.

OncoZenge expands the board with Hilde Furberg

OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has at an Extraordinary Shareholders Meeting today resolved on expanding the board with Hilde Furberg ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.Hilde Furberg (born 1958) represents Linc AB and is an independent consultant and a professional board member. She has broad senior leadership experience, coming from her over 35 years in sales, marketing, strategy and general management roles in pharmaceuticals and biotechnology. Her experience is

OncoZenge raises MSEK 10 ahead of spin-off and separate listing

OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has today resolved on a directed share issue in accordance with the press release from November 16[th], 2020 (the “Directed Issue”). The Directed Issue of MSEK 10 is the first step of the secured financing in OncoZenge of MSEK 70 in total. The share issue is carried out to secure OncoZenge’s initial working capital requirements ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.On November 16[th], 2020, it was announced that OncoZenge, through

Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge

STOCKHOLM, November 30[th], 2020 – Moberg Pharma AB (publ) (”Moberg Pharma” or the ”Company”) has obtained a positive decision confirming that the Swedish Tax Agency shares the Company’s assessment that the Company’s proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, which means that the distribution will not be subject to taxation for the Company’s shareholders.The board of directors of Moberg Pharma has proposed that the extraordinary general meeting to be held tomorrow, 1 December 2020,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe